Learn about the world’s most advanced ex vivo immuno-oncology models.
KIYATEC AND MAYO CLINIC COLLABORATE TO FIGHT OVARIAN CANCER Collaboration aims to validate the accuracy ex vivo 3D (EV3D) cell culture predictions against ovarian cancer patient outcomes Greenville, S.C. | June 16, 2016 07:00 EDT – KIYATEC, a leader in emerging 3D ex vivo predictive cancer diagnostics, today announced a collaboration with Mayo Clinic toRead More
KIYATEC Announces Inaugural Scientific Advisory Board Members Experts to Provide Invaluable Insight and Guidance to Advance Predictive Cancer Diagnostics. Members: Carlos L. Arteaga, MD (Vanderbilt University), David Kaplan, PhD (Tufts University), Anil Sood, MD (MD Anderson) Greenville, S.C. | April 4, 2016 – KIYATEC, a leader in emerging 3D ex vivo predictive cancer diagnostics, today announced theRead More
Three KIYATEC abstracts accepted for poster presentations during 2016 AACR Conference in New Orleans KIYATEC, a private company prioritizing accurate ex vivo prediction of patients’ response to drug treatment, received acceptance of three posters for presentations during the upcoming AACR conference. GREENVILLE, SC, March 21, 2016– KIYATEC Inc. is pleased to announce that three abstractsRead More
National Cancer Institute (NCI) Awards KIYATEC $1.725M to Develop Cancer Stem Cell (CSC) Expansion Technology Contract Funds 3D Cell Culture Technology Platform to Expand CSCs for Small Cell Lung Cancer (SCLC) Model Development GREENVILLE, SC | October 22, 2015 – KIYATEC announced today the award of a Fast Track Phase I and Phase II Small Business Innovation Research (SBIR)Read More
National Institute of Biomedical Imaging and Bioengineering (NIBIB) Awards KIYATEC $225,000 to Develop 3D Platelet Bank Contract Funds 3D Microbioreactor Bone Marrow Mimetic for Platelet Production GREENVILLE, SC | September 30, 2015 – KIYATEC announced today that it has been awarded a $225,000 Small Business Innovation Research (SBIR) Phase I Grant from the National Institute ofRead More